This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Peptoid probes for Alzheimer's disease (AD)-associated antibodies	<p><i>In vitro</i> and human serum studies suggest that antibodies from AD patients could be useful for diagnosing the disease. Screening AD patient serum against a microarray of peptide-like compounds called peptoids led to the identification of three peptoids that bound antibodies from AD patients but not antibodies from healthy or Parkinson's disease (PD) controls. Next steps include identifying the antigens bound by the AD-associated, peptoid-reactive antibodies and running studies of large AD patient cohorts to test the prognostic power of the peptoid probes.</p> <p>Opko Health Inc. is using the technology to develop techniques for the early detection of neurodegenerative disease and cancer.</p> <p>SciBX 4(4); doi:10.1038/scibx.2011.121 Published online Jan. 27, 2011</p>	Patents pending; licensed to Opko Health	<p>Reddy, M.M. <i>et al. Cell</i>; published online Jan. 7, 2011; doi:10.1016/j.cell.2010.11.054 Contact: Thomas Kodadek, The Scripps Research Institute, Jupiter, Fla. e-mail: kodadek@scripps.edu</p>